Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Report
May 11, 2023
Multiple Sclerosis – Current Treatment – Current Treatment: Physician Insights – Multiple Sclerosis (US)
Numerous disease-modifying therapies (DMTs) have entered the multiple sclerosis (MS) disease landscape in recent years, and many of them are next-generation alternatives within existing classes…
Report
April 14, 2023
Multiple Sclerosis | Unmet Need | Primary-Progressive Multiple Sclerosis | US/EU5 | 2019
Roche/Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS), the first of its kind. According to…
Report
April 13, 2023
Multiple Sclerosis – Unmet Need – Unmet Need – Primary-Progressive Multiple Sclerosis (US/EU)
Roche / Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS)—making it the first agent to…
